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Abstract
Background. Receptor tyrosine kinases such as epidermal growth factor receptors (EGFRs) and their downstream 
signaling pathways such as the Ras-Raf-mitogen-activated protein kinase (MAPK) pathway play important roles in 
glioblastoma (GBM). This study investigated the safety, pharmacokinetics, and efficacy of sorafenib (Ras/Raf/MAPK 
inhibitor) in combination with erlotinib (EGFR inhibitor) for treatment of recurrent GBMs.
Methods. Patients with recurrent GBM were eligible. A novel sequential accrual trial design was used, where pa-
tients were sequentially accrued into separate treatment arms in phase I and phase II investigations to optimize 
recruitment efficiency. In phase I, a standard 3 + 3 format was used to identify dose-limiting toxicities (DLTs), deter-
mine maximum tolerated dose (MTD), and investigate pharmacokinetics. Phase II followed a 2-stage design with 
the primary endpoint being 6-month progression-free survival (PFS6).
Results. Sixteen patients were recruited for phase I, and the MTD was determined to be sorafenib 200 mg twice 
daily and erlotinib 100 mg once daily. DLTs include Grade 3 hypertension, Grade 3 elevated liver transaminases, 
and Grade 4 elevated lipase. While erlotinib did not affect sorafenib levels, sorafenib reduced erlotinib levels. In 
phase II, 3 of 19 stage 1 participants were progression free at 6 months. This did not meet the predetermined effi-
cacy endpoint, and the trial was terminated.
Conclusion. This study identified the MTD and DLTs for sorafenib and erlotinib combination therapy for recurrent 
GBMs; however, efficacy data did not meet the primary endpoint. This study also demonstrates the feasibility of a 
novel sequential accrual clinical trial design that optimizes patient recruitment for multiarm studies, which is par-
ticularly effective for multicenter clinical trials.
Phase I/II study of sorafenib in combination with 
erlotinib for recurrent glioblastoma as part of a 3-arm 
sequential accrual clinical trial: NABTC 05-02
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Key Points
• The MTDs for sorafenib and erlotinib are 200 mg twice daily (BID) and 100 mg 
once daily (QD), respectively.
• Sorafenib and erlotinib therapy does not improve PFS6 for recurrent GBM.
• A sequential accrual trial design can streamline studies of multiple treatments.
Glioblastoma (GBM) is the most common primary CNS 
malignancy in adults with an annual incidence of nearly 
12,000 cases in the United States.1 Despite multimodality 
treatment with surgery, chemotherapy, and radiotherapy, 
5-year survival is less than 7%.1 After initial therapy, tumor 
recurrence almost always occurs, often within months fol-
lowing the completion of adjuvant radiotherapy. Once GBM 
recurs, response to second-line therapies is limited; chemo-
therapy response rate is below 10% and is often short-lived, 
and 6-month progression-free survival (PFS) is typically less 
than 15% for most treatment regimens.2 Thus, novel ther-
apies are desperately needed for GBM patients.
The Ras-Raf-mitogen-activated protein kinase (Ras/Raf/
MAPK) pathway is known to play a major role in tumor 
cell growth and survival, and is responsible for transdu-
cing signals from receptor tyrosine kinases (RTKs) that are 
known to drive GBM growth.3,4 These RTKs include epi-
dermal, vascular endothelial, or platelet-derived growth 
factor receptors (EGFR, VEGFR, or PDGFR, respectively). 
Sorafenib, a bi-aryl urea, is an inhibitor of RAF1 and b-RAF 
kinase family members (which are part of the Ras/Raf/
MAPK pathway), and it has been proposed as a prom-
ising therapy for GBM. More specifically, sorafenib has 
been shown to inhibit proangiogenic receptor tyrosine 
kinases such as VEGFR-2, PDGFR-, and VEGFR-3,5–7 all 
of which are implicated in the disease process of GBM. 
However, sorafenib performed poorly in past clinical trials. 
A  previous phase II trial adding sorafenib to standard 
GBM treatment failed to show an improvement in PFS.8 
Furthermore, sorafenib alone does not seem to inhibit the 
MAPK pathway efficiently, even in systemic solid tumors.9 
Thus, given these data, it is unlikely that sorafenib alone 
would be sufficient to alter the disease course of GBM.
Over past decades, EGFR has become one of the most 
widely studied therapeutic targets in GBM.10 EGFR is 
overexpressed in most GBMs,4 and about 30% have EGFR 
gene rearrangements resulting in the expression of a con-
stitutively active mutant EGFR vIII.11 Various inhibitors of 
EGFR have been developed (eg, erlotinib); however, re-
sults from previous phase II investigations of erlotinib 
suggest that EGFR blockade alone is unlikely to be effec-
tive in GBM.12–16 While the EGFR and Ras/Raf/MAPK path-
ways are intricately connected insofar that Ras/Raf/MAPK 
is activated downstream of EGFR activation,17 they likely 
play significant roles in GBM independent of each other. 
For example, EGFR activation can lead to activation of 
other signaling pathways known to promote cell growth 
(eg, P13K/Akt/mTOR), and the Ras/Raf/MAPK pathway can 
transduce signals for other growth factor receptors impli-
cated in GBM (eg, VEGFR and PDGFR). Thus, we hypothe-
size that dual Ras/Raf/MAPK and EGFR blockade may be 
more effective for GBM compared to monotherapy as it 
would not only amplify the inhibitory effects on the EGFR/
Raf/Ras/MAPK axis but also exert inhibitory effects on other 
pathways downstream of EGFR as well as other RTKs.
The North American Brain Tumor Consortium (NABTC) 
05-02 trial is a phase I/II study to assess the safety and ef-
ficacy of sorafenib in combination with other promising 
therapeutic agents for recurrent GBM. Three combina-
tion therapy arms were studied: arm 1 was sorafenib + 
erlotinib, arm 2 was sorafenib + temsirolimus (an mTOR 
inhibitor), and arm 3 was sorafenib + tipifarnib (a P13K/
Akt/mTOR inhibitor). In this report, results from arm 1 
(sorafenib + erlotinib) are presented; results from arms 2 
and 3 have been published previously.18,19 To optimize pa-
tient accrual efficiency, a novel sequential accrual design 
was implemented. To our knowledge, NABTC 0502 is the 
first phase I/II clinical trial to employ a sequential accrual 
format. Details of this trial design will be discussed in 
this report.
Importance of the Study
This study provides new data on the toxicities 
and efficacy of sorafenib and erlotinib combi-
nation therapy in recurrent GBM. In contrast 
with previous studies, this study identified 
elevated lipase as a dose-limiting toxicity, 
leading to a lower maximum tolerated dose. 
Furthermore, this study provides new evidence 
that sorafenib in combination with erlotinib 
does not improve progression-free survival 
at 6 months. Finally, this study demonstrates 
the feasibility of a novel sequential accrual 
clinical trial design, which can significantly im-
prove phase I and phase II patient recruitment 
efficiency for studying multiple experimental 
agents, particularly in multicenter settings. 
Detailed documentation of this clinical trial 
design in this report can serve as a roadmap 
for investigators seeking to optimize patient 
accrual across multiple investigational treat-
ments in future clinical trials.













Adult patients ≥18  years of age with histologically con-
firmed intracranial GBM or gliosarcoma and unequiv-
ocal tumor progression determined by MRI were eligible. 
Baseline imaging was required to be within 14 days prior 
to trial registration, and steroid dose was required to be 
stable for at least 5 days. Patients were required to have 
recovered from toxic effects of prior drug therapy: 28 days 
from any investigational agent, 28  days from prior cy-
totoxic therapy, 14  days from vincristine, 42  days from 
nitrosoureas, 21  days from procarbazine administration, 
and 7 days from noncytotoxic agents. Patients who under-
went recent resection of recurrent or progressive tumor 
were eligible as long as they had recovered from the ef-
fects of surgery, regardless of presence of postsurgical 
residual disease. Patients were required to have failed 
radiation therapy 42  days or more prior to registration. 
Furthermore, patients were required to meet the following 
criteria: Karnofsky performance status (KPS) ≥ 60, adequate 
bone marrow function (WBC ≥3000/mcl, ANC ≥1500/mm3, 
platelet count ≥100,000/mm3, and hemoglobin ≥10 gm/dL), 
total bilirubin within normal limits, liver transaminases 
(AST/ALT) ≤2.5× upper limit of normal, creatinine < 1.5 mg/
dL, INR <1.5 (or < 3.0 for patients on chronic anticoagulation 
therapy). Patients receiving enzyme inducing antiepileptic 
drugs (EIAEDs) or any other CYP3A4 inducers (except dex-
amethasone) were excluded. For women of child-bearing 
age, contraception was required for trial participation, and 
pregnant patients were excluded. For the phase I compo-
nent, patients may have had any number of prior disease 
relapses and treatments; however, for the phase II com-
ponent, patients could not have had treatment for more 
than 2 prior relapses. Finally, patients in arm 1 (sorafenib 
+ erlotinib) could not have received prior sorafenib, AE788, 
PTK 787, or other EGFR targeting agents.
This study was approved by each participating center’s 
institutional review board and was conducted in accord-
ance with federal and institutional regulations for clin-
ical trials. All patients signed informed consent indicating 
that they were aware of the investigational nature of this 
study. Furthermore, patients also signed authorization for 
the release of their protected health information and were 
entered into the NABTC study database prior to therapy 
initiation.
Patient Accrual and Treatment Plan
The NABTC 05-02 trial included 3 treatment arms testing 
combinations of signal transduction targeted agents with 
sorafenib as the backbone agent. In addition to sorafenib, 
patients in arms 1, 2, and 3 received erlotinib, temsirolimus, 
and tipifarnib, respectively. Here, we present the data 
from arm 1—sorafenib and erlotinib—of this trial and dis-
cuss the sequential accrual design in detail. Sorafenib and 
erlotinib were supplied by the Cancer Therapy Evaluation 
Program, Division of Cancer Treatment and Diagnosis, 
National Cancer Institute, under a cooperative agreement 
with Bayer Healthcare and Genentech. Oral sorafenib was 
administered twice daily and oral erlotinib once daily. Each 
treatment cycle was 4 weeks (28 days).
Phase I study
We employed a standard 3  +  3 dose-escalation format, 
enrolling 3 patients per cohort per arm at a time. Sequential 
accrual of eligible patients is described in Figure 1, and pa-
tients were assigned to treatment arms as follows:
• Patients #1–3: Arm 1 at dose level 0.
• Patients #4–6: Arm 2 at dose level 0.
• Patients #7–9: Arm 3 at dose level 0.
• Patients #10–12: Arm 1 at the next appropriate dose 
level per standard protocol, after patients #1–3 com-
pleted treatment cycles and DLTs are assessed.
• Patients #13–15: Arm 2 at the next appropriate dose 
level per standard protocol, after patients #4–6 com-
pleted treatment cycles and DLTs are assessed.
• Patients #16–18: Arm 3 at the next appropriate dose 
level per standard protocol, after patients #7–9 com-
pleted treatment cycles and DLTs are assessed.
• Patients #19–21: Arm 1 at next appropriate dose.
• Patients #22–24: Arm 2 at next appropriate dose.
• Patients #25–27: Arm 3 at next appropriate dose.
This pattern continued until either the maximum dose 
level was deemed safe or a DLT and MTD was reached for 
each arm. In arm 1, patients initially received sorafenib 
at 200 mg BID and erlotinib at 100 mg QD. Subsequently, 
doses were escalated or de-escalated according to a pre-
determined schedule depending on the number of DLTs 
observed per cohort, with the dosing schedule provided 
in Table 1. Toxicities were graded according to the National 
Cancer Institute Common Toxicity Criteria version 4 (http://
ctep.cancer.gov/reporting/ctc.html). DLTs included any 
Grade 4 hematologic toxicity; Grade 3 thrombocytopenia 
lasting ≥7 days; any Grade 3 or 4 nonhematologic toxicity 
(electrolyte imbalances, diarrhea, nausea, and vomiting 
are only considered DLTs if they remain Grade 3 or 4 de-
spite maximal medical therapy); any intolerable Grade 2 
nonhematological, or Grade 3 hematological toxicity re-
quiring dose reduction during the first treatment cycle 
(28 days); and any toxicity resulting in a treatment delay of 
more than 1 week during the first treatment cycle (28 days). 
MTD was defined by the highest dose level at which less 
than one third of patients experienced DLTs.
Phase II study
Here, we employed a 2-stage design for all treatment 
arms. Sequential accrual of eligible patients is described in 
Figure 1 and patients were assigned as follows:
• Patients #1–19: Arm 1 stage 1 (sorafenib and erlotinib).
• Patients #20–38: Arm 2 stage 1 (sorafenib and 
temsirolimus).
• Patients #39–57: Arm 3 stage 1(sorafenib and tipifarnib).
• Patients #58–70: Arm 1 stage 2, if prespecified efficiency 
endpoint is reached in arm 1 stage 1.
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• Patients #71–83: Arm 2 stage 2, if prespecified efficiency 
endpoint is reached in arm 2 stage 1.
• Patients #84–96: Arm 3 stage 2, if prespecified efficiency 
endpoint is reached in arm 3 stage 1.
Nineteen patients were recruited to stage 1 of each arm, 
and if PFS at 6  months (PFS6, defined radiographically) 
passed a prespecified efficiency threshold, 14 additional 
patients were recruited to stage 2 of that arm. Therapy was 
continued for each patient until completion of 24 cycles or 
radiographically confirmed disease progression, which-
ever occurred first. If Grade 3 or 4 toxicities developed, 
treatment was held until abnormalities are adequately 
reversed, at which point a lower dose level was adminis-
tered. Treatment was terminated if therapy was held for 
longer than 28 days for any reason.
Patient Evaluation
A complete history, physical, and neurological examina-
tion were performed at baseline. Electrocardiogram, MRI 
confirming tumor progression, and laboratory tests to 
confirm normal organ function including bone marrow, 
hepatic and renal, were performed within 14 days prior to 
registration. Serum β-HCG was measured for women of 
childbearing potential.
During the study, complete neurologic and physical 
exams were performed prior to every treatment cycle 
(every 4 weeks). Adverse events were evaluated weekly 
during the first treatment cycle for phase I patients and 
after each treatment cycle (once every 4 weeks) for phase 
II patients. Patients were instructed to monitor and 
record their blood pressure in a Blood Pressure Diary. 
For laboratory testing, patient CBC (with differential) and 
platelet counts were evaluated weekly during the initial 
treatment cycle for phase I patients and every 2 weeks 
for phase II patients. Other laboratory tests were evalu-
ated weekly during the initial treatment cycle of all pa-
tients and then every 4 weeks (prior to each subsequent 
cycle) thereafter. MRI was performed prior to every other 
cycle (every 8 weeks) and at 6 months following initiation 
of therapy to ensure assessment of primary endpoint. If 
patient achieved PFS at 6 months or partial/complete re-
sponse, imaging results were evaluated by central film 
review at University of California San Francisco. The 
response was determined by the MacDonald criteria20 
to ensure comparability to historical data as this study 
predated the development of more modern evaluation 
methods such as the RANO criteria.21
When possible, all patients were followed for overall sur-
vival. Survival was evaluated every 3 months for patients 
who discontinued treatment due to disease progression. 
Patients who discontinued treatment due to other reasons 
continued to be followed until disease progression or initi-







































Figure 1. Schematic of novel sequential accrual clinical trial design.
  













All phase I participants and the first 10 phase II partici-
pants were evaluated for pharmacokinetic studies. Whole 
blood samples (5 mL for erlotinib and 6 mL for sorafenib) 
were collected in heparinized (sodium or lithium) con-
taining, nonseparator tubes by venipuncture (heparin 
lock) or by central venous catheter if present. During 
sampling, the first 1 mL of blood was discarded prior to 
collection. Samples were serially collected on days 1, 15, 
and 28 at the following time points: baseline, 1, 2, 4, 6, 8, 
and 12 h postadministration and at 24 h prior to drug ad-
ministration. Erlotinib was started on day 1 followed by 
sorafenib on day 2 after the 24 h post-erlotinib sample. 
Discontinuation of erlotinib was planned for day 22 as a 
washout period prior to the evaluation of a single-dose 
sorafenib on day 28; however, due to a protocol over-
sight, erlotinib was continued through day 28. Blood 
samples were centrifuged within 30  min at 3000  rpm 
for 15  min. Plasma samples were stored at −70°C until 
analysis.
Analytical methods
Concentrations of erlotinib and its O-demethylated iso-
meric metabolites (OSI-420/OSI-413 collectively called 
OSI-420) in plasma were analyzed using a validated 
liquid chromatography-mass spectrometry (LC/MS) 
method with atmospheric pressure chemical ionization 
(APCI) in the positive ion mode as previously described.22 
The lower limit of quantitation of erlotinib and OSI-420 
was 1  ng/mL. Analytical grade erlotinib, OSI-420 and 
CP-396,059 (IS) were obtained from OSI Pharmaceuticals. 
Analytical standards for sorafenib and sorafenib n-oxide 
were obtained from Toronto Research Chemicals, Inc. 
Tolnaflate (IS) was obtained from Sigma–Aldrich. A val-
idated LC/MS method using APCI was initially devel-
oped for the detection of sorafenib and its n-oxide 
metabolite (Bayer 673472). Because of the dynamic 
range (1–1000  ng/mL) for the assay, significant plasma 
dilutions were required for quantitation. Therefore, a 
previously published HPLC assay was implemented 
and validated.23 Briefly, duplicate calibration standards, 
quality control (QC), or patient samples were spiked with 
the IS followed by acetonitrile protein precipitation then 
double extracted with diethyl ether. The absolute recov-
eries of sorafenib and sorafenib n-oxide were 70% and 
75%, respectively. After evaporation, the residue was re-
constituted with methyl alcohol and subjected to linear 
gradient elution on a reverse-phase C18 column with UV 
detection (254  mm). Calibration curves (7 points) were 
linear (R2 > 0.99) from 0.5 μg/mL (LLQ) to 12 μg/mL for 
sorafenib and 0.08 μg/mL to 4 μg/mL for the n-oxide me-
tabolite. The interday precision for sorafenib/n-oxide was 
7.1%/7.5%, 7.5%/11%, and 8.5%/7.3% for the low, medium, 
and high OC samples, respectively.
The pharmacokinetic parameters for erlotinib, sorafenib, 
and their respective metabolites were analyzed by 
noncompartmental analysis. Peak concentrations (Cpmax) 
were determined by inspection of each individual’s con-
centration–time curve. The area under the concentration–
time curve was calculated using the linear trapezoidal rule 
up to the last measurable time point (AUC0-t). Differences 
between the kinetic variables were evaluated using an 
unpaired 2-tailed t-test. P values less than 0.05 were con-
sidered statistically significant.
Statistical Considerations
The primary endpoints for the phase I component were the 
determination of the MTD of sorafenib + erlotinib, charac-
terization of toxicities, and evaluation of drug interactions 
via pharmacokinetics studies. The primary endpoint for 
the phase II component was 6-month PFS (PFS6), and 
this study was designed to have 90% power to detect an 
increase of PFS6 to 35% from 15% (historical data from 8 
consecutive negative phase II trials for GBM2). Thus, it was 
determined that 19 patients were to be assigned to stage 
1 and 14 patients to stage 2. If 4 of the 19 patients in stage 
I were progression free at 6 months, the arm would con-
tinue to stage 2 accrual for a total recruitment of 33 pa-
tients. Overall, if more than 7 patients were progression 
free at 6 months, the treatment would be considered ef-
fective (α < 0.1 with a 1-tailed binomial test of a single 
proportion).
  
Table 1. Phase I Dose Levels, Enrollment, and DLTs
Dose Level Sorafenib Dose Erlotinib Dose Enrolled DLTs Replaced
−2 200 mg QD 75 mg QD 0 0 0
−1 200 mg QD 100 mg QD 0 0 0
0 (MTD) 200 mg BID 100 mg QD 6 1a 0
1 400 mg BID 100 mg QD 7 2b 1d
2 400 mg BID 150 mg QD 3 2c 0
aGrade 3 Elevated AST/ALT.
bGrade 3 Hypertension and Grade 4 Elevated Lipase.
cGrade 3 and Grade 4 Elevated Lipase.
dPatient received half dose of sorafenib for first 14 days.
  




Sixteen eligible patients were enrolled into the phase I   
component of the sorafenib + erlotinib treatment arm, and 
characteristics are given in Table 2. In brief, there were 9 
men and 7 women. The median age was 53 years, with a 
range of 36–70. Median KPS was 90 (range: 70–100), and 
patients had a median of 2 prior chemotherapy regimens. 
Two patients had previously received bevacizumab.
MTDs and toxicities
The number of patients and events at dose levels 0, 1, and 
2 are given in Table 1. At the initial sorafenib 200 mg twice 
daily (BID) and erlotinib 100  mg once daily (QD) dose 
level (DL0), 1 of 6 patients developed DLT (Grade 3 ele-
vated AST/ALT). At the sorafenib 400 mg BID and erlotinib 
100 mg QD dose level (DL1), 2 of 6 patients developed DLT 
(Grade 4 elevated lipase and Grade 3 hypertension). At 
the sorafenib 400 mg BID and erlotinib 150mg QD dose 
level (DL2), 2 of 3 patients developed DLT (Grades 3 and 4 
elevated lipase). Of note, 1 patient in the first DL1 cohort 
experienced Grade 4 elevated lipase, and at the time of 
data review in August 2007, Grade 4 elevated lipase was 
not considered a DLT as it was deemed unlikely related to 
study drugs. However, in the second DL1 cohort (March 
2008), a Grade 3 hypertension event was observed. This 
prompted a re-evaluation of the first DL1 cohort, resulting 
in the reclassification of the elevated lipase event as a DLT 
and making DL0 the MTD.
Pharmacokinetic results
Samples from 18 patients treated with erlotinib 100  mg 
daily plus sorafenib 200 mg or 400 mg BID were available 
for pharmacokinetic (PK) analyses. Table 3 shows the PK 
parameters for the daily administered erlotinib 100 mg for 
all patients and for 6 patients who had a complete set of 
blood samples available for analysis on days 1, 15, and 28. 
No statistical difference was observed between the day 1 
PK parameters and the day 15/28 steady-state parameters. 
With continuous dosing of erlotinib, exposure did not 
increase over time. The accumulation ratio was 1.2 which 
is in contrast to the accumulation ratio of 2.8 with single-
agent erlotinib.15,24
The following patient illustrates our observed influ-
ence of sorafenib on the PK of erlotinib: patient was started 
on erlotinib 150  mg continuously days 1 through 28 plus 
sorafenib 400 mg BID days 2 through 7. Sorafenib was held 
for 6 days as a result of Grade 3 elevation in lipase and re-
started on day 15 at a reduced dose of 200 mg BID. Day 1 
erlotinib Cpmax and AUC were within the reported range for a 
150 mg dose (538 ng/mL and 8.6 µg × h/mL, respectively). On 
day 15, prior to resuming sorafenib, we observed increased 
Cpmax and AUC (1349 ng/mL and 16 µg × h/mL, respectively) 
as well as an expected accumulation of erlotinib (accumula-
tion ratio of 2.5). However, on day 28 (13 days after resuming 
sorafenib), Cpmax and AUC were significantly reduced (506 ng/
mL and 10.7 µg × h/mL, respectively). This case highlights the 
effects of sorafenib on erlotinib’s PK parameters and also 
provides insight into the rapidity of the onset/offset.
Pharmacokinetic results for sorafenib—the arithmetic 
mean steady-state peak concentrations (Cpmax) and area 
under the plasma time curve (AUC0–12) for sorafenib and 
its n-oxide metabolite for the dose levels of 200 mg and 
400  mg on days 15 and 28—are summarized in Table  4. 
Overall, there were no observed differences in the kinetic 
parameters for sorafenib in the presence of erlotinib com-
pared to prior reports.25,26
Phase II Component
Patient characteristics
Nineteen eligible patients were enrolled into the phase II 
component (Table 2). Among participants, 9 were men and 
10 women. Median age was 52 years (range: 30–76), and 
median KPS was 90 (range: 60–100). Patients had a median 
of 2 prior chemotherapy treatments, and 6 patients had 
received prior bevacizumab therapy. All patients received 
the MTD of the study agent identified in the phase I com-
ponent, which was sorafenib 200  mg BID and erlotinib 
100 mg QD. Treatment was terminated for 4 patients prior 
to confirmed disease progression. One patient experi-
enced leakage at surgical site, requiring re-operation; post-
operative course was complicated with further leakage and 
treatment was held for longer than 28 days and ultimately 
  
Table 2. Patient Characteristics
Patient Characteristics Phase I Phase II
Number of evaluable patients 16 19
Sex
 Male 9 (56.3%) 9 (47.4%)
 Female 7 (43.8%) 10 (52.6%)
Age (y)
 Median 53 52
 Range 36–70 30–76
KPS
 Median 90 90
 100 4 (25.0%) 2 (10.5%)
 90 6 (37.5%) 8 (42.1%)
 80 5 (31.3%) 5 (26.3%)
 70 1 (6.3%) 3 (15.8%)
 60 0 (0.0%) 1 (5.3%)
Histology
 Glioblastoma 16 (100%) 19 (100%)
Prior chemotherapy regimens
 Median 2 2
 1 7 (38.9%) 7 (36.8%)
 2 8 (50.0%) 12 (63.2%)
 3 1 (6.3%) 0 (0.0%)
  











terminated. One patient terminated treatment due to ad-
verse events. Two patients withdrew from the trial fol-
lowing initiation therapy.
Efficacy data
Fifteen patients were evaluable for radiological response. 
No patient showed complete or partial response. Three 
patients remained progression free at 6 months and 3 pa-
tients’ time of disease progression was unknown. Among 
the 12 patients with known time of disease progression, 
PFS rate at 6 months (PFS6) was 18.8%, and median PFS 
was 1.8 months. Six patients were alive at 12 months, rep-
resenting a 12-month overall survival (OS12) of 31.6%; me-
dian OS was 5 months (Supplementary Figure 1). Median 
number of 4-week treatment cycles was 2 (range: 1–9). As 
fewer than 4 patients were progression free at 6 months, 
the sorafenib + erlotinib treatment arm was terminated 
and did not progress to stage 2 recruitment.
Toxicity data
All patients from phase I  and phase II components (35 
total) of this trial were evaluated for treatment toxicity. 
Overall, sorafenib and erlotinib were well tolerated at the 
MTD. All Grade 3 and 4 events deemed related (possible 
or higher) to sorafenib + erlotinib combination therapy are 
detailed in Table 5.
Discussion
This phase I/II study of sorafenib and erlotinib identi-
fied the MTD of sorafenib as 200 mg BID and of erlotinib 
as 100 mg QD and demonstrated that while erlotinib did 
not affect the PK of sorafenib, sorafenib reduced erlotinib 
levels. Furthermore, this study shows that while sorafenib 
and erlotinib are well tolerated at the MTD, this combina-
tion therapy does not improve PFS6 for recurrent GBM 
compared to historical controls.
In the phase I  component, MTD was established at 
sorafenib 200  mg BID and erlotinib 100  mg QD after 
observing 2 DLTs (1 Grade 4 elevated lipase and 1 Grade 
3 hypertension) among 6 patients at the next higher dose 
(DL1). This resulted in an MTD that is lower than previously 
reported for sorafenib and erlotinib for treatment in GBM 
and other cancers.27–30 Notably, the NABTT 0502 trial, con-
ducted at the same time as the current study, defined the 
MTD of sorafenib as 400 mg BID and of erlotinib as 150 mg 
QD. The difference in MTD between the NABTT trial and the 
current trial is largely because in this study, Grade 3 and 4 
elevated lipase are classified as DLTs, while in the NABTT 
trial, Grade 3 and 4 elevated lipase events are not (unless 
there are associated elevations in amylase or symptoms 
of pancreatitis). Elevated lipase is a common toxicity of 
sorafenib,26 however, clinical significance of isolated and 
asymptomatic Grade 3 or 4 elevated lipase due to sorafenib 
  
Table 3. Pharmacokinetic Values of Erlotinib and Its Metabolite OSI-420
Erlotinib 200 mg BID
Cpmax (ng/mL)
All Patients Day 1 (n = 14) Day 15 (n = 16) Day 28 (n = 10)
 Erlotinib (mean ± SD) 443 ± 155 662 ± 373 653 ±653
 OSI-420 (mean ± SD) 31 ± 14 62 ± 44 66 ± 52
Matched Patients Day 1 (n = 6) Day 15 (n = 6) Day 28 (n = 6)
 Erlotinib (mean ± SD) 483 ± 197 729 ± 385 806 ± 54a
 OSI-420 (mean ± SD) 28 ± 19.4 58 ± 35.1 88 ± 54
Comparison with other trials (mean) Day 1 Day 28  
 Current Trial 443 653  
 Yamamoto et al.24 571 1023  
AUC0-4 (μg × h/mL)
All Patients Day 1 (n = 14) Day 15 (n = 16) Day 28 (n = 10)
 Erlotinib (mean ± SD) 6.3 ± 2.61 6.9 ± 4.59 7.7 ± 4.05
 OSI-420 (mean ± SD) 0.34 ± 0.16 0.62 ± 0.46 0.86 ± 0.46
Matched Patients Day 1 (n = 6) Day 15 (n = 6) Day 28 (n = 6)
 Erlotinib (mean ± SD) 6.8 ± 3.13 8.2 ± 4.95 9.0 ± 4.03b
 OSI-420 (mean ± SD) 0.32 ± 0.15 0.61 ± 0.46 0.95 ± 0.45
Comparison with other trials (mean) Day 1 Day 28  
 Current Trial 443 653  
 Yamamoto et al.24 571 1023  
aP value = .20 (Day 1 vs Day 28).
bP value = .20 (Day 1 vs Day 28).
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is unclear. Thus, further investigations are needed to deter-
mine the significance of isolated and asymptomatic Grades 
3 or 4 elevated lipase in GBM patients treated with combi-
nation therapies that include sorafenib.
The PK parameters for sorafenib are consistent with pub-
lished reports and not influenced by the coadministration of 
erlotinib.31,32 Definitive conclusions regarding sorafenib’s 
effect on erlotinib PKs could not be determined due to the 
relatively infrequent sampling schedule. However, from 
our study, sorafenib appears to alter the PK of erlotinib. 
With continuous dosing, the exposure of erlotinib did not 
increase over time. Similarly, past studies of sorafenib 
and erlotinib combinations also reported that sorafenib 
seems to affect erlotinib PK, lowering its plasma levels. 
This phenomenon was also observed in the NABTT trial.27 
Interestingly, combination of sorafenib plus gefitinib, 
another EGFR inhibitor, shows a similar PK pattern.33 
Erlotinib and gefitinib share the same structural backbone 
and are metabolized by CYP3A4/5. Increased activation of 
CYP3A4 enzyme velocity rather than induction is one of the 
suggested mechanisms.34–36 In this 2-substrate allosteric 
binding model, sorafenib and erlotinib could bind simulta-
neously to CYP3A4 active sites. Sorafenib acting as an ac-
tuator or effector would either enhance erlotinib’s affinity 
for CYP3A4 or induce conformational changes in CYP3A4 
that regulate its enzyme activity. Whatever the mech-
anism for the interaction, the clinical relevance of reduced 
erlotinib accumulation by sorafenib is unknown.
In the phase II component, only 3 patients in the stage 
1 cohort remained progression free at 6 months. As this 
  
Table 4. Pharmacokinetic Values of Sorafenib and Its Metabolite N-oxide
Sorafenib 200 mg BID
Cpmax (µg/mL)
All Patients Day 15 (n = 9) Day 28 (n = 7) P value
 Sorafenib (mean ± SD) 5.51 ± 2.68 4.67 ± 2.10 .51
 N-oxide (mean ± SD) 1.5 ± 1.51 0.8 ± 0.38 .33
Comparisons with other trials (geometric mean) Day 14–15 Day 28  
 Current Trial 4.4 4.0  
 Furuse et al. 26 3.4 4.2  
 Strumberg et al. 25 — 4.0  
AUC0-12 (µg × h/mL)
All Patients Day 15 (n = 9) Day 28 (n = 7) P value
 Sorafenib (mean ± SD) 45.85 ± 21.51 40.29 ± 18.6 .60
 N-oxide (mean ± SD) 11 ± 11.1 6.1 ± 3.28 .26
Comparisons with other trials (geometric mean) Day 14–15 Day 28  
 Current Trial 38 35  
 Furuse et al. 26 26 32  
 Strumberg et al. 25 — 35  
Sorafenib 400 mg BID
Cpmax (µg/mL)
All Patients Day 15 (n = 6) Day 28 (n = 3) P value
 Sorafenib (mean ± SD) 8.4 ± 5.18 4.1 ± 0.56 .20
 N-oxide (mean ± SD) 2.0 ± 1.75 0.9 ± 0.55 .37
Comparisons with other trials (geometric mean) Day 14–15 Day 28  
 Current Trial 6.2 4.1  
 Furuse et al. 26 4.7 3.3  
 Strumberg et al. 25 — 5.4  
AUC0-12 (µg × h/mL)
All Patients Day 15 (n = 6) Day 28 (n = 3) P value
 Sorafenib (mean ± SD) 62.4 ± 38 38.7 ± 9.61 .34
 N-oxide (mean ± SD) 15 ± 14.7 9.7 ± 6.54 .57
Comparisons with other trials (geometric mean) Day 14–15 Day 28  
 Current Trial 43 38  
 Furuse et al. 26 34 29  
 Strumberg et al. 25 — 48  
  











was below the predetermined efficacy threshold of at 
least 4 progression-free patients, the trial was termin-
ated. The lack of efficacy may be explained by multiple 
factors. First, the dose of sorafenib and erlotinib is lower 
than the dose used in trials for other solid tumors. As 
discussed previously, this is mainly due to the classifi-
cation of Grade 3 and 4 elevated  lipase as a DLT in the 
current trial. Second, it is possible that this combination 
therapy is not sufficient to overcome the multitude of re-
dundant growth signal activations in GBM. Finally, the 
ability of sorafenib and erlotinib to penetrate the blood–
brain barrier is limited, as studies have shown that both 
drugs can be transported out of the CNS via ABCG2 ef-
flux pumps.37,38 Additionally, the pharmacokinetic interac-
tion between erlotinib and sorafenib leading to reduced 
levels of erlotinib may have also contributed to the lack 
of efficacy. Despite these postulations, it is possible 
that sorafenib and erlotinib combination therapy may 
simply be ineffective as a treatment for recurrent GBM; 
thus, further studies of this combination therapy are not 
warranted.
While all 3 treatment arms of NABTC 05-02 were nega-
tive, this trial was able to demonstrate the feasibility of a 
novel sequential accrual study design of multiple experi-
mental treatments. Traditionally, each combination therapy 
studied in NABTC 05-02 would have been structured as 
its own phase I/II trial and coordinating patient recruit-
ment for each of the 3 trials would have been difficult, es-
pecially in multicenter settings. In essence, with NABTC 
05-02, we were able to combine 3 clinical trials into 1 trial 
with a systematically streamlined patient accrual process 
to significantly increase the possibility that patients can 
be enrolled in a study arm at any given time. This trial de-
sign benefits not only patients and their families but also 
reduces the time needed to investigate multiple drugs as 
well as help mitigate concerns over available protocol slots 
in a multicenter study. However, to maximize the utility of 
this novel sequential accrual design, treatment arms must 
share similar inclusion/exclusion criteria, therapy cycle 
lengths, and cohort sizes. Thus, this trial design may be 
best suited for investigating multiple combination ther-
apies sharing one common agent as in the case of NABCT 
05-02.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
Advances online.
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